Image Alternative Text

Optimizing treatment requires all the answers

Get the complete
picture before
choosing treatment.

NCCN-guideline recommended testing for solid tumors.1-13

All solid tumors Bladder Breast Cholangiocarcinoma Colorectal Endometrial Gastric and Gastroesophageal
GIST Lung Melanoma Ovarian Pancreatic Prostate Thyroid
ALK ATM BRAF BRAF V600E BRAF V600K BRCA1 BRCA2 CDK12 EGFR ERBB2 (HER2) ESR1 FGFR2 FGFR3 IDH1 KIT KRAS MET MSI NRAS NTRK PDGFRA PIK3CA RET ROS1 There are FDA-approved therapies available for all solid tumors with NTRK fusions and MSI status.
Current as of September 2020.

Targeted treatment improves outcomes.

Patients with targetable alterations experience higher response rates to targeted therapy vs immunotherapy.1

Targeted Therapy: 56-83% Response Rates. Immunotherapy: 4-26% Response Rates. Targeted Therapy: 56-83% Response Rates. Immunotherapy: 4-26% Response Rates.

Liquid biopsy offers critical advantages over tissue testing.

Leading with liquid-first testing can help inform clinical decisions faster than tissue.

Liquid biopsy begins with a minimally-invasive blood draw and delivers Complete Genomic Results in 7 Days. Tissue testing is an unpredictable process involving multiple care team members, causing up to 21 Days of diagnostic delays. Liquid biopsy begins with a minimally-invasive blood draw and delivers Complete Genomic Results in 7 Days. Tissue testing is an unpredictable process involving multiple care team members, causing up to 21 Days of diagnostic delays.
Learn About
FDA-approved Guardant360 CDx 
See The Data
View clinical evidence* 
*Disclaimer: This content has not been reviewed by the FDA. Data shown for the performance of Guardant360® Laboratory Developed Test (LDT) does not convey the performance of Guardant360 CDx.